公开(公告)号：US11925639B2

公开(公告)日：2024-03-12

申请号：US16465277

申请日：2018-02-06

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoichi Ozawa ,  Yusaku Hori ,  Kazuhiko Yamada ,  Hiroshi Kamiyama ,  Masahiro Matsuki

IPC: A61K31/4985 ,  A61K31/53 ,  A61P35/00

CPC classification number: A61K31/4985 ,  A61K31/53 ,  A61P35/00

Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.

公开(公告)号：US20210349097A1

公开(公告)日：2021-11-11

申请号：US17282193

申请日：2019-10-02

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yasuhiro Funahashi ,  Yukinori Minoshima ,  Michio Kanekiyo ,  Masahiro Matsuki ,  Yusuke Adachi ,  Kotaro Kodama

IPC: G01N33/574 ,  A61P35/04 ,  A61K31/47 ,  A61K31/436 ,  C12Q1/6886

Abstract: Biomarkers are provided that predict whether a human subject having a renal cell carcinoma is responsive to a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate) and everolimus. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a renal cell carcinoma.

公开(公告)号：US20190388420A1

公开(公告)日：2019-12-26

申请号：US16465277

申请日：2018-02-06

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Yoichi Ozawa ,  Yusaku Hori ,  Kazuhiko Yamada ,  Hiroshi Kamiyama ,  Masahiro Matsuki

IPC: A61K31/4985 ,  A61P35/00

Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.

公开(公告)号：US20190000829A1

公开(公告)日：2019-01-03

申请号：US15748980

申请日：2016-08-17

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Junji Matsui ,  Masahiro Matsuki ,  Akihiko Tsuruoka ,  Toshiyuki Tamai ,  Ryo Nakajima ,  Takuya Suzuki

IPC: A61K31/47 ,  A61P35/00 ,  A61K31/095

Abstract: A therapeutic agent for biliary tract cancer comprising 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof is provided.